Join a Perth clinical trial

A Perth clinical trial may give you access to new, innovative treatments. People who take part in a trial are often the first to access and benefit from new and emerging treatments.

We conduct clinical studies into chronic respiratory conditions, including asthma, COPD, bronchiectasis, idiopathic pulmonary fibrosis (IPF) and cystic fibrosis.

We aim to offer the best quality of care for people living with a respiratory condition

Our Unit is made up of a team of Specialists, Doctors, Registered Nurses and health science professionals. To find out if a trial is suitable for you please register with us or contact our friendly team on (08) 6457 3198. Below are some of our patient clinical trials which may be of interest to you. Click here to view our brochure for more information.

Trials Recruiting Now Closed Clinical Trials
Condition

Name

Study Outline

Eligibility & Requirements

What's Involved

Register
Asthma

Tezepelumab

The study aims to evaluate the effectiveness and safety of Tezepelumab in patients with asthma.

Aged between 18-80 with a diagnosis of asthma made by a doctor
Use of two asthma inhalers daily
At least two asthma flare-ups in the last 12 months
Current smokers excluded

You will be required to attend up to 17 visits to Sir Charles Gairdner Hospital for approximately 16 months.

Register

Alpha1 Antitrypsin Deficiency

GTi1201

Alpha 1 Antitrypsin Deficiency
Approximately 3 years
Phase III
Safety and Efficacy of two dose regimens of the study drug
Weekly infusions

18- 70 years old
Diagnosis of Alpha 1 Antitrypsin Deficiency with evidence of emphysema
No flare up of the chest in the last 5 weeks prior to the first visit
No cancer in last 5 years

You will be required to come once a week for 3 years for treatment including health checks to Sir Charles Gairdner Hospital.
CT scans of your lungs will be required on 5 occasions throughout the trial

Register

Bronchiectasis

INS1007-201

The study aims to evaluate the effect of INS1007 (study drug) compared with no study drug on time to first pulmonary exacerbation (chest flare up) over the 24-week treatment period.

Aged between 18 and 85 with a diagnosis of non-cystic fibrosis bronchiectasis.
At least two flare-ups of your bronchiectasis requiring antibiotic treatment in the last 12 months.

You will be required to attend up to 10 visits to Sir Charles Gairdner Hospital for up to approximately 8 months.

Register

IPF

CC-90001-IPF-001

The aim of this study is to evaluate the effect of CC-90001 in 200 mg tablet and 400 mg tablet, taken once daily compared with a placebo, on lung function after 24 weeks of treatment in patients with Idiopathic Pulmonary Fibrosis (IPF).

Aged 40 years or older
Have been diagnosed with IPF within the last 5 years
Forced Vital Capacity (FVC) ≥45% at screening
Percent predicted diffusion capacity of the lung for carbon monoxide (DLCO) ≥ 25% and ≤ 90% predicted at Screening
Able to walk ≥150m during the 6-minute walk test at screening
(Additional inclusion/exclusion criteria apply)

You will be required to attend a monthly visit to Sir Charles Gairdner Hospital for approximately 26 months. In the first 6 months, you will receive study treatment or placebo (2:1) in the form of oral tablets. However, after this time you will then enter a 19-month active treatment phase where you will receive either dose of study drug. Participants will continue to receive monthly check-ups with the site’s doctor during this phase.

Register

Pulmonary Arterial Hypertension

Sphinx

This study is to determine whether there are any health benefits to be gained from Apixaban, an anticoagulant medication, in patients with Systemic Sclerosis related Pulmonary Arterial Hypertension ( SSc - PAH) who are already prescribed advanced Pulmonary Arterial Hypertension (PAH) therapy.

Aged 18 – 75 years
Systemic Sclerosis related
Pulmonary Arterial Hypertension (SSc-PAH) diagnosed by a right heart catheterization

You will be required to attend at least 9 visits across a three year period at Sir Charles Gairdner Hospital. There are also monthly phone calls to assess any changes in your health.

Register

Healthy volunteers

C3671002

The study aims to evaluate an investigational vaccine against diseases caused by respiratory syncytial virus (RSV) when given at the same time as the approved annual influenza vaccine.

Healthy adults aged 65 to 85 years
Willing and able to follow a study treatment plan of scheduled study visits, lab tests and other study
Procedures for the duration of the study, approximately 12 months

You will be required to attend one longer visit to Sir Charles Gairdner Hospital to receive the investigational vaccine or placebo and also the annual approved influenza vaccine. You will then need to attend four more short visits over the next 12 months.

Register

Join a Perth clinical trial

We aim to offer the best quality of care for people living with a respiratory condition

Condition

Name

Study Outline

Eligibility & Requirements

What's Involved

Register